China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an announcement.
China Resources Pharmaceutical Group Ltd. has successfully completed the public issuance of the second tranche of its 2025 Corporate Bonds in the PRC, raising RMB400 million with a coupon rate of 1.93% per annum. The proceeds from this issuance will be used to repay interest-bearing debt, potentially strengthening the company’s financial position and operational capacity.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is known for its comprehensive range of pharmaceutical offerings and plays a significant role in the healthcare market.
YTD Price Performance: -19.85%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.56B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.